Clinical trials: Erythropoietin
Renal Effects
Renal Effects of Erythropoietin in Humans
Erythropoietin (EPO) is a glycoprotein produced mainly in the kidney. After its release to the bloodstream EPO binds to its receptor predominantly located within the bone marrow where erythropoiesis is stimulated.
- Trial name
- EPO 2012 (NCT01584921)
- Testing
- Erythropoietin (Epoetin-beta, NeoRecormon®)
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Anemia, Renal Failure, Chronic Renal Failure
Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency
The purpose of the study is to assess the effect of an early and complete correction of anemia after treatment with epoetin alfa on the rate of progression of chronic renal failure (which involves improper functioning of the…
- Trial name
- NCT00312871
- Testing
- Epoetin alfa
- Volunteers
- 217 people
- Sponsor
- Janssen Cilag S.A.S.
Anemia, Myelodysplastic Syndromes
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. Epoetin alfa may stimulate red blood cell production and be an effective treatment for anemia in patients with myelodysplastic syndrome.
- Trial name
- NCT00003681
- Testing
- epoetin alfa, amifostine trihydrate
- Where
- 12 sites in Austria, Belgium and 5 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cardiac Surgery-CABG, Cardiac Valve Replacement
EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)
EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)
- Trial name
- EPORT (NCT02802592)
- Testing
- Epogen, Normal Saline
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Johns Hopkins University
Beta-Thalassemia
Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia
OBJECTIVES: I. Determine whether arginine butyrate with or without epoetin alfa can stimulate gamma-globin chain production to a degree that decreases anemia and results in hematologic improvement in patients with thalassemia…
- Trial name
- NCT00006136
- Testing
- arginine butyrate, epoetin alfa
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Boston University
Chemotherapy Induced Anemia
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.
- Trial name
- NCT00144495
- Testing
- recombinant human erythropoietin
- Volunteers
- 104 people
- Sponsor
- Chugai Pharmaceutical
Iron Deficiency Anemia
2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.
- Trial name
- NCT00223977
- Testing
- Sodium Ferric Gluconate Complex, Oral Iron
- Where
- 43 sites in United States, Bulgaria and 6 more
- Volunteers
- 146 people
- Sponsor
- Watson Pharmaceuticals
Anemia, End Stage Renal Disease
Epodure Therapy of Anemia in End Stage Renal Disease on Dialysis With Epodure Skin Implant
In this End Stage Renal Disease (ESRD) patients who need Erythropoietin (epo) hormone will get it by a small implant of skin using their own skin, the implant will be treated in the laboratory and programmed to secrete Epo.
- Trial name
- NCT01555515
- Testing
- implantation of autologous skin graft after ex-vivo treatment, Subcutan implantation of autologus skin graft after ex-vivo treatment
- Volunteers
- 4 people
- Sponsor
- Medgenics Medical Israel Ltd.
Oral Lichen Planus
Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus
The purpose of this study is to compare the clinical efficacy of erythropoietin gel containing a solution of 4000 units with triamcinolone acetonide 0.1% gel in the treatment of symptomatic oral lichen planus (OLP)
- Trial name
- NCT06135259
- Testing
- erythropoietin, Triamcinolone acetonide
- Volunteers
- 18 people
- Sponsor
- Ain Shams University
Anaemia
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
This is a four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from stable rhEPO to GSK1278863 in approximately 68…
- Trial name
- NCT01587924
- Testing
- GSK1278863, rhEPO
- Where
- 62 sites in United States, Canada and 4 more
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Acute Myocardial Infarction
Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction
Hypothesis: Based on available pharmacokinetic data from healthy volunteers we hypothesize that the administration of a cumulative dose of 210μg of the continuous erythropoietin receptor activator, Mircera® (Roche), during 3…
- Trial name
- BEATSTEMIPi (NCT01093820)
- Testing
- methoxy-polyethyleneglycol epoetin beta
- Where
- Switzerland
- Volunteers
- 8 people
- Sponsor
- University Hospital, Basel, Switzerland
Myelodysplastic Syndromes
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.
The goal of the present study is to assess, through a randomized phase II trial, the efficacy and safety of Lenalidomide with or without Epoetin beta in transfusion-dependent, ESA-resistant, IPSS low and intermediate-1 risk MDS…
- Trial name
- NCT01718379
- Testing
- Lenalidomide, Epoetin beta
- Where
- 48 sites in France, Monaco
- Volunteers
- 132 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Anemia, Chronic Kidney Disease
Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis
The purpose of this study was to determine the dose ranges of peginesatide administered intravenously or subcutaneously that maintained hemoglobin in participants on dialysis whose hemoglobin values were stable on epoetin (alfa…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00434330
- Testing
- peginesatide
- Where
- 15 sites in Bulgaria, Romania and 1 more
- Volunteers
- 91 people
- Sponsor
- Affymax
Renal Dialysis
To Evaluate the Efficacy of Eleutherococcus Senticosus for Subjects Under Renal Dialysis
This is a randomized, double-blind, placebo-controlled, parallel comparison trial to evaluate the efficacy and safety of Eleutherococcus Senticosus taken orally by patients under regular dialysis.
- Trial name
- NCT03210519
- Testing
- Eleutherococcus senticosus
- Volunteers
- 21 people
- Sponsor
- Chung Shan Medical University
Blood Transfusion, Blood Transfusion, Autologous
A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery
The purpose of this study is to determine whether epoetin alfa will enable self-donation of at least 4 units of blood during the 2-week period before surgery (which is a shorter period of time than the conventional 3-week blood…
- Conditions
- Blood Transfusion, Blood Transfusion, Autologous, Orthopedic Procedures, Orthopedic Surgery
- Trial name
- NCT00270075
- Testing
- epoetin alfa
- Volunteers
- 80 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cerebral Palsy
Allogeneic UCB Therapy With EPO in Children With CP
This randomized controlled study aims to evaluate the efficacy and safety of allogeneic umbilical cord blood therapy combined with erythropoietin for children with cerebral palsy.
- Trial name
- NCT01991145
- Testing
- Umbilical Cord Blood therapy, Erythropoietin alfa, Rehabilitation
- Where
- South Korea
- Volunteers
- 92 people
- Sponsor
- MinYoung Kim, MD, PhD
Chronic Renal Failure
EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure
The purpose of the study is to evaluate the effectiveness, safety and clinical outcome of Epoetin alfa with dosing regime in accordance with Summary of Product Characteristics in the treatment of anemia in predialysis.
- Trial name
- NCT00338000
- Testing
- Epoetin alfa
- Volunteers
- 292 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Anaemia
Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Daprodustat administration has the potential, by virtue of increasing hypoxia-inducible factor (HIF) levels, to increase oral iron absorption and incorporation into hemoglobin (Hgb).
- Trial name
- NCT03457701
- Testing
- Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Healthy
PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).
Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow.
- Trial name
- NCT07025681
- Testing
- Erythropoietin alfa
- Where
- Bangladesh
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Incepta Pharmaceuticals Ltd
Sepsis, Systemic Inflammation
Effect of APC and Epo on the Inflammatory Response During Sepsis
An observational study to determine the effect of APC and Epo in reducing the systemic inflammatory response during severe sepsis.
- Trial name
- NCT00229034
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's